东方生物(688298.SH)：2025年净亏损5.64亿元

Core Viewpoint - Dongfang Biological (688298.SH) reported a total operating revenue of 959 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 15.83%. However, the company experienced a net loss attributable to shareholders of 564 million yuan, a decline of 6.54% compared to the previous year [1] Financial Performance - Total operating revenue reached 959 million yuan, up 15.83% year-on-year [1] - Net profit attributable to shareholders was -564 million yuan, down 6.54% year-on-year [1] - Net profit excluding non-recurring gains and losses was -589 million yuan, a decrease of 3.04% year-on-year [1] - Basic earnings per share were -2.93 yuan, down 8.92% year-on-year [1] - Weighted average return on net assets was -8.90%, a decline of 1.36 percentage points year-on-year [1] Business Development - The company's main business maintained steady growth, but significant investments in strategic development across various technology platforms led to overall losses [1] - Factors contributing to the net loss included foreign exchange losses, reduced contributions from interest income, increased depreciation and amortization expenses, and provisions for asset impairment [1]